- GLP-1 medication users showed a 44% reduction in cardiovascular hospitalization risk.
- Aon's study highlighted a potential for significant healthcare cost savings for employers.
- Aon launched a GLP-1 weight management program for U.S. employees with eMed.
Aon plc (AON, Financial), a leading global professional services firm, has released a pioneering workforce-focused analysis on GLP-1 medications and their impact on healthcare costs and employee health. The study, which analyzed data from over 50 million commercially insured individuals, shows that GLP-1 medications, when paired with holistic support, can significantly reduce long-term healthcare costs and improve workforce productivity.
Key findings from Aon's analysis demonstrate that GLP-1 users experienced a 44% reduction in hospitalization risks due to major cardiovascular events, including strokes and heart attacks, over a 24-month period. Furthermore, after the initial treatment costs, GLP-1 users displayed cost growth rates that were half that of a control group, leading to improved health conditions overall.
In light of these findings, Aon has announced the launch of its own subsidized GLP-1 weight management program for U.S. employees. This initiative, in collaboration with eMed, offers a comprehensive support framework that includes AI-powered biometric tracking, at-home blood tests, and 24/7 side effect management. Given that obesity affects 40% of U.S. adults and costs the economy up to $1.72 trillion annually, Aon's program aims to address this issue by enhancing workforce health and productivity.
"Our analysis shows that GLP-1 medications, when complemented by a holistic adherence program, represent a transformative opportunity to manage chronic diseases and enhance quality of life," remarked Greg Case, CEO of Aon. He emphasized the dual benefits of this strategy, which can drive meaningful health improvements and deliver long-term economic value.
